---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-095481"
form_type: "8-K"
ticker: "BOLD"
cik: "0001782303"
company_name: "Boundless Bio, Inc."
filed_at: "2024-08-12T23:59:59+00:00"
generated_at: "2026-05-31T10:05:43.755188+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Boundless Bio Q2 net loss $17M; delays BBI-355 combo data to H2 2025

## Summary
- Net loss of $17.0M for Q2 2024 vs $12.4M in Q2 2023; R&D expense $14.7M, G&A $4.7M.
- Cash, equivalents, and short-term investments $179.3M as of June 30, 2024.
- BBI-355 combo cohort enrollment slower than expected; initial proof-of-concept data now H2 2025.
- BBI-825 first patient dosed in April 2024; initial data also expected H2 2025.
- Workforce reduced and operations streamlined to extend runway into Q4 2026.

## SEC filing metadata
- accession: 0000950170-24-095481
- form_type: 8-K
- ticker: BOLD
- cik: 0001782303
- company_name: Boundless Bio, Inc.
- filed_at: 2024-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782303/000095017024095481/0000950170-24-095481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782303/000095017024095481/bold-20240812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-095481
- JSON: https://secwatch.observer/filing/0000950170-24-095481.json
- Plain text: https://secwatch.observer/filing/0000950170-24-095481.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.